The latest PLSP published in Future Oncology provides a summary of the GioTag study, that looked at how the drugs afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. The PLSP, written by Professor Maximilian J Hochmair, is a summary of the final analysis of the GioTag study published in Future Oncology last year.
By publishing both the original article and PLSP is the same journal, we are able to link the publications to make readers of either article aware of the original and PLS versions.
Read the PLSP in full here.
The original article, entitled ‘Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study’, published in Future Oncology, can be found here.